Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9033971 | 0.78 | OXTR (0.37) | OPRM1OXTRHDAC9MAOAMAOB | |
| SCHEMBL8080060 | 0.76 | HDAC9 (0.47) | OPRL1OPRM1OPRK1HDAC1HDAC2 | |
| SCHEMBL14182625 | 0.75 | OXTR (0.39) | OXTRMAOAMAOB | |
| SCHEMBL236649 | 0.72 | OXTR (0.42) | OXTRMAOAMAOB | |
| SCHEMBL2977414 | 0.71 | OPRM1 (0.38) | OPRL1OPRM1OPRK1OXTROPRD1 | |
| SCHEMBL31069767 | 0.70 | CYP1A2 (0.38) | OPRL1OPRM1OPRK1HDAC9ALOX15 | |
| SCHEMBL28644317 | 0.69 | OXTR (0.39) | OXTRMAOAMAOB | |
| SCHEMBL7971051 | 0.69 | OXTR (0.39) | OXTRMAOAMAOB | |
| SCHEMBL27514284 | 0.68 | OXTR (0.30) | OXTR | |
| SCHEMBL10536039 | 0.68 | OPRL1 (0.43) | OPRL1OPRM1OPRK1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252707-A1 | Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin | UNIVERSITE DE LIEGE (BE) | 2006-11-09 | — | — | US | disclosed |
| EP-1644006-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR THE PREVENTION OF ATHEROSCLEROSIS FROM INFECTIOUS ORIGIN | Université de Liège (BE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004105769-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR THE PREVENTION OF ATHEROSCLEROSIS FROM INFECTIOUS ORIGIN | UNIVERSITE DE LIEGE (BE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252707-A1 | Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin | APOB, SCARB1, TLR1 | OPRL1 4483/4885OPRM1 4857/4885OPRK1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.